Jisandai/Bingtonsha usage and dosage guide

As the world's first pan-genotypic oral hepatitis C treatment drug, Epclusa has greatly simplified the treatment process for the majority of patients. Its standard dosage form is compound tablets, each containing 400 mg of sofosbuvir and 100 mg of velpatasvir. The standard recommended dose is one tablet per day, taken continuously for 12 weeks (that is, 3 boxes constitute a complete course of treatment). There is no need to eat while taking the medicine, but it is recommended to take it regularly every day to maintain a stable drug concentration in the body. This course of treatment is sufficient to achieve virological cure in most patients without cirrhosis or with compensated cirrhosis.

During the treatment process, patients do not need to use interferon or ribavirin in combination, which is a major advantage that distinguishes it from the older generation of treatment options. However, for high-risk patients with decompensated cirrhosis or previous treatment failure, doctors may evaluate whether to combine ribavirin or extend the treatment duration. Before starting treatment, it is necessary to confirm that the patient is positive for HCV RNA, rule out HBV co-infection, and evaluate liver function status; changes in viral load, transaminase levels, and possible adverse reactions should be monitored during medication.

Epclusa is well tolerated, and most patients experience mild adverse reactions during treatment. Symptoms such as mild fatigue, headache, and loss of appetite generally do not affect the continuity of treatment. However, certain drugs should be avoided during medication, such as rifampicin, St. John's wort and other drugs that are known to interfere with the third-generation metabolism of Ginseng. For patients with moderately or severely impaired renal function, although sofosbuvir is partially excreted by the kidneys, it is still recommended to use it under the guidance of a doctor before careful evaluation. After treatment, it is recommended to recheck HCV RNA at weeks 12 and 24 to evaluate whether SVR (sustained virological response) has been achieved. If the virus is not detected, it is considered clinically cured.

Reference: https://www.epclusa.com/